Latest Commercialization News

Brazilian Critical Minerals has achieved a significant milestone in its Ema project by successfully demonstrating magnesium sulphate migration and pH reduction in field trials, validating its in-situ recovery method for rare earth elements.

Viridis Mining and Minerals has been selected for a major Brazilian government funding package to accelerate its Colossus rare earth elements project, marking a pivotal step in diversifying global critical mineral supply chains.

Qualitas Real Estate Income Fund has declared its May 2025 distribution, offering investors a 7.42% annualized return based on net tangible assets. The fund continues to focus on Australian real estate loans secured by mortgages.

Carnaby Resources has revealed preliminary VTEM survey results identifying multiple new conductors at its Greater Duchess Copper Gold Project, highlighting promising targets in a largely unexplored southern corridor.

Ionic Rare Earths’ Brazilian joint venture, Viridion, has been selected for significant government funding to accelerate rare earth refining and magnet recycling, marking a major step in Brazil’s strategic push for a secure, sustainable supply chain.

Minbos Resources reports strong 2024-25 field trial results for its phosphate fertilizer PRIMEIRO™ in Angola, while expanding its product range with PRIMEIRO PLUS+, a blended NPKS solution tailored to local soils and crops.

Empire Energy Group has successfully closed and upsized its Share Purchase Plan to $7 million, raising crucial funds to advance its Beetaloo Basin projects. The capital raise strengthens the company’s cash position ahead of key operational milestones.

Control Bionics is on track for its strongest financial year yet, driven by robust US and Australian sales and promising global trials of its NeuroStrip® device.

FireFly Metals Ltd has announced a flow-through share offer aiming to raise approximately A$11.2 million, targeting Canadian investors to fund regional exploration drilling. This offer complements a broader capital raising strategy to advance development at the Ming Mine and other key projects.

Hawsons Iron Limited is raising up to $1 million through a discounted Share Purchase Plan to fund critical project development while continuing strategic investor discussions.

Mesoblast reports positive FDA progress on accelerated approval for Revascor in ischemic heart failure and plans a pivotal trial to extend Ryoncil’s label to adults with graft versus host disease, while its US commercial launch outpaces expectations.

Island Pharmaceuticals has reported encouraging Phase 2a/b trial results for ISLA-101, demonstrating meaningful reductions in dengue viral load and symptoms in humans. The findings support further clinical development of this antiviral candidate.